The application of these medical devices is also escalating due to the increasing preference for minimally invasive procedures, as they are effective and cause minimal pain. The usage of neurostimulation devices via these treatment procedures provides immediate pain relief to patients. Additionally, the growing consciousness about mental health and increasing awareness regarding the treatments for mental disorders will boost the usage of neurostimulation devices in the coming years. The implantable systems target specific cranial, peripheral, cortical, spinal, and subcortical nerve structures to regulate the neuronal activity, thereby providing therapeutic effects for an array of neuropsychiatric disorders.

Moreover, recent developments in neuroimaging and neurotechnology and enhanced understanding of neurocircuitry will amplify the usage of such devices for treating a wide range of psychiatric and neurological diseases. The surging need for advanced neurostimulation devices has resulted in hefty investments in research and development (R&D) by manufacturers, including ImThera Medical, MED-EL GmbH, Neuronetics Inc., Aleva Neurotherapeutics SA, Cochlear Ltd., St. Jude Medical Inc., Boston Scientific Corporation, Synapse Biomedical Inc., Neurosigma Inc., Medtronic PLC, NDI Medical LLC, LivaNova PLC, and EnteroMedics Inc.

Currently, medical device companies are offering internal and external neurostimulation devices to offer better treatment to patients. Internal devices include sacral nerve stimulation (SNS), vagus nerve stimulation (VNS) devices, gastric electric stimulation (GES), spinal cord stimulation (SCS), and deep brain stimulation (DBS), and cochlear implants (CI). Whereas external devices available in the market include transcutaneous electrical nerve stimulation (TENS) devices and transcranial magnetic stimulation (TMS).

In recent years, the application of non-invasive neurological devices has significantly increased in the treatment of depression, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and other similar disorders among children and adolescents, globally. Whereas, invasive devices like VNS and DBS have proven efficient in treating epilepsy and dystonia among young patients. With the constant developments in the invasive remodulation technology, the application of internal devices and implants will amplify in the coming years. This would also help in expanding the current knowledge base of neurocircuitry in the future.

According to P&S Intelligence, the North American neurostimulation device market holds the top position globally. This is due to the surging cases of chronic pain, neurological disorders, and other chronic ailments in the region. Neurological diseases like Parkinson’s disease, migraine, traumatic brain injury (TBI), spinal cord injury (SCI), stroke, epilepsy, tension-type headache (TTH), and Alzheimer’s disease and other dementias affect a large chunk of the U.S. population. TTH, migraine, stroke, Alzheimer’s disease and other dementias, and SCI are the most prevalent diseases, affecting around 121.6 million, 68.5 million, 7.8 million, 2.9 million, and 2.2 million individuals, respectively, in the U.S.

Thus, the rising prevalence of neurological disorders and increasing investments in R&D will amplify the usage of internal and external neurostimulation devices in the foreseeable future.